Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06143514 · ClinicalTrials.gov registry record
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
A clinical trial of Relapsing Multiple Sclerosis, sponsored by TG Therapeutics.
- Recruiting
- Registry status
- 16
- Enrollment target
- 4
- Study locations
NCT06143514 is a study of Relapsing Multiple Sclerosis that is actively recruiting participants, run by TG Therapeutics. The registered enrollment target is 16 participants, below the 2,169-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06143514, a study of Relapsing Multiple Sclerosis, is actively recruiting participants, sponsored by TG Therapeutics.
- RECRUITING
- Registry status
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (4)
California
- PROVIDE Virtual Research Coordination Center - San Francisco
Georgia
- PROVIDE Virtual Research Coordination Center - Smyrna
North Carolina
- PROVIDE Virtual Research Coordination Center - Wilmington
Tennessee
- PROVIDE Virtual Research Coordination Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-03-26 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06143514
The ClinicalTrials.gov registry entry for NCT06143514 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,169-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (99% lower). The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT06143514 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Georgia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06143514 about?
NCT06143514 is a clinical study titled "A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk". The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).
What is the current status of trial NCT06143514?
This trial is currently recruiting. The enrollment target is 16 participants. The study started on 2024-03-26. Estimated completion is 2026-06-30.
What conditions does trial NCT06143514 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT06143514?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT06143514?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06143514 being conducted?
This trial has 4 study locations across California, Georgia, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
RECRUITING · Phase 4
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RECRUITING
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
RECRUITING · Phase 3
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.